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ABSTRACT
Natural killer cells can be divided into fi ve subpopulations based on the relative expression of CD16 
and CD56 markers. The majority of natural killer cells are CD56dim, which are considered to be 
the main cytotoxic effectors. A minority of the natural killer cells are CD56bright, and function as 
an important source of immune-regulatory cytokines. Shifts of these subsets have been reported 
in patients with chronic hepatitis C virus infection. We sought to investigate the shift of natural 
killer subsets among Egyptian patients with chronic HCV and to analyze the inﬂ uence of interferon 
therapy on this shift. We applied a ﬂ ow cytometric analysis of peripheral blood natural killer sub-
sets for 12 interferon-untreated and 12 interferon-treated patients with chronic HCV, in compari-
son to 10 control subjects. Among interferon-untreated patients, there was a signifi cant reduction 
of CD56-16+ (immature natural killer) cells. Among interferon-treated patients, the absolute count 
of natural killer cells was reduced, with expansion of the CD56bright subset and reduction of the 
CD56dim16+ subset. Natural killer subset counts were not signifi cantly correlated to HCV viral load 
and were not signifi cantly different among interferon responders and non-responders. In conclusion, 
HCV infection in Egyptian patients has been observed to be statistically and signifi cantly associated 
with reduction of the CD56-16+NK subset, while a statistically signifi cant expansion of CD56bright and 
reduction of CD56dim16+ subsets were observed after interferon therapy. Further studies are required 
to delineate the molecular basis of interferon-induced shift of natural killer subsets among patients 
with HCV.
Keywords: natural killer cells, natural killer subsets, chronic hepatitis C, innate immunity, interferon.
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INTRODUCTION
Natural killer (NK) cells form 10-15% of the 
peripheral blood lymphocyte population. They 
are found in several lymphoid and non-lym-
phoid compartments of organs, such as spleen, 
liver, and lungs.1 The identifi cation of NK cells 
can be based on their morphology, function, or 
phenotype. Morphologically, NK cells are typed 
as large granular lymphocytes having a ki dney-
shaped nucleus, a high cytoplasm to nucleus 
volume ratio, and containing large intracyto-
plasmic azurophilic granules.2 Functionally, NK 
cells are thought to have two important roles: 
target cell killing and cytokine production. 
With regards to target cell killing, NK cells dif-
fer from T cells in that their cytolytic response 
does not require prior sensitization, and they 
are capable of destroying MHC I-mismatched 
haematopoietic and lymphoid cells.3 Regarding 
cytokine production, NK cells secrete mainly 
interferon-γ (IFN-γ), tumor necrosis factor-α 
(TNF-α) and granulocyte monocyte colony-
stimulating factor (GM-CSF), which enable 
them to regulate the host immune mechanism 
locally.4 Phenotypically, they are distinguished 
from T and B lymphocytes by the absence of 
the T-cell receptor/CD3 complex and immu-
noglobulin receptors on their cell surface.5 Be-
sides the lack of certain markers on their sur-
face, the presence of CD56 is used as a marker 
for NK cells in humans. CD56 has been shown 
to be an isoform of the neural cellular adhe-
sion molecule.6 The expression of CD16, which 
is involved in the antibody dependent cellular 
cytotoxicity (ADCC) mediated by NK cells, 
is also used as a phenotypic marker.7 There-
fore, NK cells are phenotypically defi ned as 
CD56+CD16+CD3- cells. In human peripheral 
blood, fi ve NK cell subpopulations can be iden-
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tified on the basis of the relative expression of CD16 and 
CD56 markers; CD56bright CD16-, CD56bright CD16+, CD56-
dim CD16+, CD56dim CD16-, and CD56- CD16+. CD56dim 
cells are the main mediators of NK cytotoxicity, as they 
contain high levels of perforin, whilst CD56bright act as an 
important source of immunoregulatory cytokines.8,9 
Hepatitis C virus (HCV) infects over 170 million peo-
ple worldwide.10 A minority of infected persons may re-
solve the acute stage of infection and clear the virus, but 
most patients develop a life-long infection, making HCV 
a leading cause of chronic liver disease, cirrhosis and 
hepatocellular carcinoma.11 The host immune response 
to HCV antigens is thought to determine whether viral 
clearance or chronic infection occurs. Hepatotropic vi-
ruses induce production of type I IFN by hepatocytes and 
other cells in the liver, which, in turn, promotes infiltra-
tion of NK cells in virus infected livers.12 The production 
of type I IFN and other cytokines (including IL-12, IL-15, 
and IL-18) by hepatocytes activates NK cells and induces 
IFN-γ production by them. The IFN-γ produced by NK 
cells recruits activated T cells to the liver. It is noteworthy 
that IFN-γ produced by NK cells plays a major role in liv-
er infiltration of CD4 and CD8 T cells. It has been shown 
in animal models that deliberate depletion of NK cells be-
fore a hepatotropic viral infection leads to inhibition of a 
virus-specific T cell response, as well as inhibition of liver 
injury.13 Human NK cells co-cultured with HCV replicon 
inhibit the replicon expression at protein and RNA levels 
by secreting antiviral factors, including IFN-γ.14 Thus, NK 
cells could also potentially contribute towards control of 
HCV replication. It is possible that an adequate NK cell 
response may control hepatotropic viruses such as HCV, 
even in the absence of virus-specific immune responses. 
This notion is supported by the observation that, like hu-
mans, a certain percentage of HCV-infected chimpanzees 
can clear the virus spontaneously, and this clearance does 
not correlate with the appearance of acquired immuni-
ty.15 However, the potential importance of NK cells in 
the control of HCV was disputed in a study that demon-
strated that depletion of CD8 T cells by mAb aggravates 
HCV infections in animal models.16 It is noteworthy that 
about one third of human and chimpanzee NK cells ex-
press CD8, and depletion of CD8 T cells by anti-CD8 an-
tibodies would also deplete CD8 NK cells. Therefore, the 
results from such studies should be interpreted with care. 
Meier et al.17 identified significantly reduced numbers of 
total NK cells and a striking shift in NK subsets, with a 
marked decrease in the CD56dim cell fraction compared 
to CD56bright cells in HCV infections. This shift influenced 
the phenotype and functional capacity (IFN-γ produc-
tion and killing) of the total NK pool. The aim of this 
work was to assess the influence of interferon therapy and 
HCV infection on NK subsets among Egyptian patients.
MATERIAL AND METHODS
Study design
This is a cross-sectional analytical study, as we are measur-
ing exposure (± interferon) and outcome (NK subsets) at 
the same time.
Study subjects
Twenty four patients, attending either Suez Canal Univer-
sity Hospital or Kasr El-Aini Hospital, were divided into two 
groups. Patients with chronic HCV who had never received 
interferon at any time during their course of illness comprised 
an interferon-untreated group (n = 12). Patients who suffered 
from chronic HCV infection and had been receiving standard 
interferon therapy for 24 weeks comprised an interferon-treat-
ed group (n = 12). The standard treatment protocol included: 
interferon (interferon-alpha 2a), three million units, three times 
per week for 48 weeks. Patients were eligible for inclusion in this 
study after 24 weeks of therapy. Patients co-infected with HIV 
or HBV were excluded from this study. A normal control group 
was comprised by healthy HCV negative blood donors (n = 
10). Written informed consent was obtained from all subjects.
Clinical history and examination
A detailed history and clinical examination were carried out 
for all groups. They were diagnosed as chronic hepatitis if 
the following criteria were present after a six month follow-
up: a) signifi cant and persistent symptoms, b) ﬂ uctuating 
or persistently elevated ALT and AST (> 1.5 fold of normal 
levels), normal serum albumin and prothrombin time, c) ul-
trasonography revealed an enlarged bright texture ± portal 
tract thickening and ± normal spleen. Liver biopsy was done 
for the untreated group. Hepatic injury was assessed using 
the histological activity index (HAI) as modifi ed by Ishak.18 
This consisted of a necro-inﬂ ammatory grading score (range 
0 to 18; 0 = no activity, 18 = severe activity) and a fi brosis 
staging score (range 0 to 6; 0 = no activity, 6 = cirrhosis).
Laboratory investigations
Venous blood samples (10 mL in EDTA and plain tubes) 
were drawn from each subject. Serum samples were obtained 
after clotting of the blood. For PCR testing, serum samples 
were stored at -80 °C until the time of assay. All samples were 
subjected to the following laboratory investigations:
1 – Complete blood count using an automated cell coun-
ter (Cell Dyne, Abbott Diagnostics).
2 – Liver function tests:
a) Alanine aminotransferase (ALT), aspartate ami 
notransferase (AST), total bilirubin, direct bilirubin, se-
rum albumin, and alkaline phosphatase (Cobas Integra 
Auto Analyzer, Roche).
b) α-fetoprotein was analysed by VIDAS autoanalyzer 
(Biomerieux, France).
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3 – Viral hepatitis markers: HCV antibodies (HCV-EIA, 
Abbott Laboratories and HBsAg (Elecsys1010, Roche Diag-
nostic GmbH) were assessed.
4 – Flow cytometry analysis: NK cell subsets were assessed 
by ﬂ ow cytometry using FACS Calibur (BD Bio-sciences, 
San José, CA, USA). Cells were labeled with mAb against 
CD3 APC (UCHT1), CD16 FITC (B-E16), and CD56 PE 
(MOC-1). Monoclonal antibodies against CD3, CD16 and 
CD56 were purchased from IQProduct (Groningen, Neth-
erlands). A sample of 20 µL of each monoclonal reagent was 
added to 100 µL of whole EDTA blood in 12×75 test tubes 
and incubated at room temperature for 15 min in the dark. 
Red blood cells were lysed using FACS Lyse reagent (BD, 
USA) and centrifuged at 2000 rpm for 5 min. The superna-
tants were discarded and the cells were washed twice with 
phosphate-buffered saline (PBS), re-suspended in 300 µL 
of PBS. Data were analyzed using FACS Calibur and Flowjo 
software (TreeStar, Ashland, OR, USA). The typical forward 
and side scatters were used for lymphocytes gating. Gated 
lymphocytes were further gated by selecting CD3- popula-
tion. CD3- cells were divided according to the expression of 
CD56 and/or CD16. Accordingly, NK cells were subgrouped 
into CD56bright or CD56dim and further defi ned by CD16 ex-
pression. 
5 – PCR: Quantitative HCV real-time PCR was per-
formed for untreated patients before the start of interferon 
treatment, using a Light Cycler-RNA Master Hybridization 
Probe system in accordance with the manufacturers’ instruc-
tion (Roche diagnostic, Mannheim, Germany). The lower 
detection limit is < 1000 IU/mL. Qualitative PCR was per-
formed for treated patients at 24 weeks of treatment. HCV-
RNA was isolated by the QIAmp RNA viral kit (Qiagen, 
Hildene, Germany). HCV-RNA was reverse transcribed into 
cDNA, amplifi ed by PCR (Qiagen), and detected by electro-
phoresis in 2% agarose gel stained with ethidium bromide. 
The PCR product (270 bp) was detected using an ultraviolet 
trans-illuminator.
Statistical analysis
Statistical analysis was done using SPSS program version 
11. Data were presented as mean ± standard deviation. The 
Kruskal-Wallis test for analysis of non parametric data was 
used to compare between groups followed by Dunnett’s 
post-hoc test. Pearson correlation analysis was used when 
appropriate. Statistical signifi cance was considered at the 
5% level of probability (p < 0.05).
RESULTS
The interferon-untreated patients (n = 12) had ages rang-
ing from 29 to 53 (42.7 ± 8) years. Seven were female and 
five were male, and their duration of hepatic illness ranged 
from 12 to 50 (28 ± 16) months. The interferon-treated 
patients (n = 12) had ages ranging from 35 to 58 (45.5 ± 
7) years. Three were female and nine were male, and the 
duration of their hepatic illness ranged from 18 to 53 (31 
± 15) months. Control subjects (n = 10) had ages rang-
ing from 38 to 50 (44.7 ± 5) years. Seven were male and 
three were female. The study subjects were matched for 
age and sex.
Clinical, histological and virological features of INF-un-
treated and treated patients are listed in Table 1, and the routine 
laboratory data of the studied groups are listed in Table 2.
Table 1. Clinical, histological and virological features of IFN-untreated and IFN-treated patients
  IFN-untreated IFN-treated
  n = 12 n = 12 
Risk factor    
 Anti-Bilhazial injection 2 3
 Blood transfusion 2 0
 Tooth extraction 5 6
 Tattooing 2 2
 Surgical intervention 5 2
Histology    
 Grading 6.9 ± 1.8 ND
 Staging 2.9 ± 1.3 ND
Viral load    
 Quantitative HCV - RNA(IU/mL×103) 296 ± 349 ND
 Qualitative PCR ND 7 cases negative HCV-RNA
   5 cases positive HCV-RNA
Values are expressed as mean ± standard deviation. ND: not determined
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Table 2. The laboratory data of IFN-untreated, IFN-treated and controls 
 Laboratory variables IFN-untreated IFN-treated Controls
  n = 12 n = 12 n = 10
 Albumin (mg/L) 4.4 ± 0.3 4.4 ± 0.36 4.3 ± 0.3
 Alkaline phosphatase (u/L) 129 ± 66† 118 ± 70* 71 ± 13
 AST (u/L) 44.5 ± 17.4§ 28.9 ± 8.9† 18.3 ± 6.1
 ALT (u/L) 63.5 ± 29§ 30.9 ± 10* 22.1 ± 5.6
 T.Bilirubin (mg/dL) 1.39 ± 2.0* 2.1 ± 4.3* 0.53 ± 0.20
 D.Bilirubin (mg/dL) 0.45 ± 0.34* 1.5 ± 3.9† 0.17 ± 0.18
 AFP (ng/mL) 9.3 ± 8.3 17.9 ± 25.1 5.2 ± 2.1
 Hemoglobin (g/dL) 14.0 ± 0.72* 11.2 ± 1.73§ 14.7 ± 0.60
 Leukocytes count (cells/uL) 6483 ± 1625 3625 ± 2092† 6440 ± 1649
 Platelets count ×103 168 ± 55† 136 ± 73† 250 ± 38
Values are expressed as mean ± standard deviation.
* Significant p < 0.05 compared with controls.
† Significant p < 0.01 compared with controls.
§ Significant p < 0.001 compared with controls.
Table 3. Lymphocytes, NK and NK subsets in IFN-untreated, IFN-treated and controls
  IFN-untreated IFN-treated Controls
 n = 12 n = 12 n = 10
Percentage of lymphocytes 32.1 ± 8.0 31.7 ± 7.8 40.7 ± 13.6
CD3- 35.6 ± 11.1 39.2 ± 11.7 42.8 ± 10.7
NK 43.7 ± 15.2 53.6 ± 14.4 44.3 ± 14
CD56bright 5.4 ± 5.2 20.2 ± 9.9§ 3.3 ± 1.72
CD56dimCD16+ 84.4 ± 10.5 68.3 ± 10.7† 80.9 ± 5.3
CD56dimCD16- 5.9 ± 4.8 7.0 ± 3.1 7.0 ± 4.3
CD56-CD16+ 3.9 ± 3.2† 4.2 ± 2.3† 8.4 ± 2.7
Absolute counts of lymphocytes 2632 ± 413 1085 ± 559† 2526 ± 784
CD3- 920 ± 269 623 ± 780† 1096 ± 457
NK 392 ± 155 204 ± 76† 471 ± 207
CD56bright 19 ± 19 44 ± 29† 13 ± 8
CD56dimCD16+ 335 ± 150 127 ± 64† 388 ± 187
CD56dimCD16- 21 ± 18 20 ± 22 27 ± 14
CD56-CD16+ 15 ± 12† 7 ± 3§ 40 ± 23
CD3- is expressed as % of gated lymphocytes, total NK is expressed as % of CD3- and NK subsets are expressed as % of NK. The 
calculated absolute numbers are expressed as cells/µL. Values are expressed as M ± SD.
* Significant p < 0.05 compared with controls.
† Significant p < 0.01 compared with controls.
§ Significant p < 0.001 compared with controls.
The proportion of total NK and NK subsets, as well as 
the absolute numbers of various NK cells in interferon-
untreated, interferon treated chronic HCV patients, and 
healthy controls are presented in Table 3. Figure 1 (a,b,c) 
shows the flow cytometry analysis for a subject from each 
group. The relative and absolute counts of CD56-CD16+ 
subset were decreased in interferon-untreated and inter-
feron treated patients when compared to controls (Fig. 2a), 
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Figure 1: Flow cytometry analysis of NK cells and NK subsets.
a) Representative dot plots of NK and NK subsets in untreated 
chronic hepatitis C subject.
b) Representative dot plots of NK and NK subsets in interferon-
treated subject.
c) Representative dot plots of NK and NK subsets in normal 
healthy subject.
Figure 2: A scatter diagram compares the absolute counts of 
NK subsets in the studied groups
a) Representative of absolute CD56-16+. 
b) Representative of absolute CD56dim 16+. 
c) Representative of absolute CD56bright.
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whereas no significant difference was detected in these 
subsets between interferon-untreated and treated pa-
tients (data not shown). Similarly, the proportion of total 
NK and NK subsets, as well as the absolute numbers of 
various NK cells in interferon responder patients versus 
non responders, did not show any significant difference 
(data not shown). The absolute numbers of total NK cells 
and both the relative and absolute numbers of CD56dim-
CD16+ cell subsets were decreased in interferon-treated 
patients when compared to interferon-untreated patients 
and controls (Figure 2b). Conversely, the relative and ab-
solute counts of CD56bright cell subsets were increased in 
interferon-treated patients when compared to interferon 
untreated patients and controls (Figure 2c).
The relative and absolute numbers of CD3+ T cells and 
CD3+/CD56+ NKT in interferon-untreated, interferon-
treated chronic HCV patients and healthy controls are 
presented in Table 4. There was a statistically significant 
decrease in the absolute counts of CD3+ T cells and CD3+/
CD56+NKT of interferon-treated patients compared with 
interferon-untreated patients and controls.
No significant correlations between NK subsets and 
HCV viremia were seen. However, a significant positive 
correlation between CD56bright counts and hepatic in-
jury, based on HAI, was detected (r = 0.63, p = 0.025). A 
significant negative correlation between CD56dimCD16+ 
counts and hepatic fibrosis was also detected (r = -0.61, 
p = 0.03).
DISCUSSION
NK cells constitute the fi rst line of host defense against in-
vading pathogens. They eliminate virus-infected cells by 
direct and indirect killing methods. Direct killing of target 
cells is achieved through the release of cytotoxic molecules, 
such as perforin and granzymes. Alternatively, apoptosis 
may be induced by over expression of Fas/FasL, TNF-α, and 
TNF-related apoptosis-inducing ligand (TRAIL)/death re-
ceptor4 (DR-4) and DR-5 interactions.19-21 Indirect killing 
of target cells may also be achieved by secretion of soluble 
factors such as IFN-γ and TNF-α. In addition, NK cells play 
a role in inhibiting virus replication by the induction of an 
antiviral state in host cells.22 Furthermore, NK cells play im-
portant immunoregulatory roles through their interaction 
with T cells, B cells and antigen-presenting cells.
In this study, we found that CD3-CD56-CD16+ cell 
counts were decreased in HCV infected patients. In con-
trast, Gonzalez et al.23 and Zarife et al.24 reported increased 
frequency of CD3-CD56-CD16+ NK cells in patients with 
chronic HCV/HIV, or in blood donors with HCV among 
European and Brazilian populations, respectively. This dif-
ference may be attributed to either host or viral heterogene-
ity, as our study was done on Egyptian populations, in which 
HCV genotype 4 is the most prevalent genotype.25
A signifi cant reduction of circulating NK cells and ex-
pansion of CD56bright, and reduction of CD56dimCD16+ sub-
sets were seen in patients with chronic HCV after interferon 
treatment. These results agreed with the data reported by 
Gonzalez et al.,23 who indicated that the CD56bright immu-
noregulatory NK cells subset temporarily expanded in re-
sponse to interferon treatment. This also agreed with the 
data reported by Saraste et al.,26 who observed an expan-
sion of CD56bright NK cells with a concomitant decrease of 
CD56dim cells in multiple sclerosis patients after 12 months 
of treatment with IFN-b. In contrast to our fi ndings, Meier 
et al.17 and Golden-Mason et al.27 reported a signifi cant re-
duction of total NK cells count and a striking shift in NK 
subsets, with a marked decrease in the CD56dim cell fraction 
compared to CD56bright cells in HCV infection. This can be 
explained by the observation that Meier et al.17 did not ex-
clude patients with history of interferon therapy and includ-
ed patients who were not on current or recent (within the 
last six months) IFN-α treatment.
CD56bright NK cells are very likely precursor cells of the 
CD56dim subset. Indeed, CD56dim NK cells display shorter 
telomeres than CD56bright NK cells from peripheral blood, 
which implies that the latter are less mature than the former. 
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Table 4. CD3+T cells and CD3+/CD56+ NKT in IFN-untreated, IFN-treated and controls
  IFN-untreated IFN-treated Controls 
 n = 12 n = 12 n = 10
CD3+T% 53.4 ± 8.9 51.8 ± 12.5 48.4 ± 9.1
CD3+/CD56+ NKT % 9.4 ± 6.1 8.6 ± 3.6 8.5 ± 3.7
Absolute counts of CD3+T 1418 ± 364 584 ± 405† 1208 ± 407
CD3+/CD56+ NKT 258 ± 198 102 ± 101* 212 ± 119
* Significant p < 0.05 compared with untreated patients and controls.
† Significant p < 0.01 compared with untreated patients and controls.
404
Expansion of CD56bright subsets was reported in patients 
who are treated daily with a low dose of IL-2.27 Since the 
mechanism of interferon-induced NK cells shift is not fully 
understood, we suggest that interferon may inﬂ uence the 
differentiation of CD56bright to CD56dim. On the other hand, 
the CD56dim16- subset was not altered either by HCV infec-
tion or interferon therapy; the main function of this subset 
is largely unknown.
In this study, no signifi cant difference in total NK cells 
and NK subsets among interferon responders were seen 
when compared to non-responders. Different results were 
reported by Panasiuk et al.,28 who found a slight increase in 
NK cell counts in patients who did not clear HCV. Also, Kha-
koo et al.,29 showed that genes encoding the NK cell recep-
tor directly inﬂ uence resolution of HCV infection. However, 
in our study, we did not assess the function of NK cells, as 
the immunodefi cient NK cells may not be able to kill virus-
infected cells. Further studies in this area, to correlate NK 
function with interferon response, are required.
In this study, a signifi cant positive correlation between 
the relative counts of CD56bright subsets with HAI was found. 
Lin et al.,30 reported that increasing activated bright NK 
cells and increasing activated apoptotic bright NK cells were 
both signifi cantly associated with increasing hepatic necro-
inﬂ ammatory grade. This fi nding may be explained by the 
fact that CD56bright subsets have immunoregulatory func-
tions and produce potent pro-inﬂ ammatory cytokines, like 
INF-γ and TNF-α.31 Absence of correlation between NK or 
its subsets with HCV viral load agrees with similar data re-
ported by Pernollet et al.,32 who found that NK populations 
did not correlate with any biochemical or viral parameters.
In conclusion, this study has shown that, in Egyptian pa-
tients, HCV infection is associated with reduction of CD56-
16+ NK subsets, and interferon-alpha therapy is associated 
with expansion of CD56bright and reduction of CD56dim16+. 
Further studies are required to delineate the molecular basis 
of interferon-induced shift of NK subsets among patients 
with HCV. As this study was conducted on two distinct 
groups of chronic HCV patients before and after interferon 
treatment, a further longitudinal study is recommended to 
address the limitations which are inherent in cross sectional 
studies of this type.
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